Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     


Delayed Nasdaq  -  04:00 2022-10-03 pm EDT
12.80 USD   +1.59%
09/15Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence
09/14BioCryst Pharmaceuticals Names Chief Medical Officer
09/14Biocryst Pharmaceuticals Inc : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia

08/18/2022 | 07:01am EDT

RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Saudi Food and Drug Authority (SFDA) has approved oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Saudi Arabia.

“There is a significant need for new treatment options for HAE in Saudi Arabia. With this approval, we continue to deliver on our commitment to bringing our oral, once-daily prophylactic therapy to as many HAE patients around the world as possible,” said Charlie Gayer, chief commercial officer of BioCryst.

In September 2021, BioCryst entered into a supply and distribution agreement with NewBridge Pharmaceuticals, which also covers the Gulf Cooperation Council (GCC) and Iraq. NewBridge Pharmaceuticals, headquartered in Dubai, United Arab Emirates (UAE), is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize U.S. Food and Drug Administration or European Medicines Agency approved innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.

“This marks the second market in the MENA region in which ORLADEYO has been approved for patients living with HAE, building on the approval in the UAE last year. We are pleased with the decision from the Saudi FDA and we are committed to continuing our work with BioCryst to bring this important therapy to patients in the GCC who are in search of a more optimal treatment option to help manage their HAE,” said Joe Henein, president and chief executive officer of NewBridge Pharmaceuticals.

ORLADEYO was safe and well tolerated in clinical trials. The most frequently reported adverse reactions in patients receiving ORLADEYO compared with placebo were back pain and gastrointestinal reactions. The gastrointestinal reactions generally occurred early after initiation of treatment with ORLADEYO, became less frequent with time and typically self-resolved.

About ORLADEYO® (berotralstat)
ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.

U.S. Indication and Important Safety Information

ORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Limitations of use
The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.

An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.

The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine).

Berotralstat is a substrate of P-gp and BCRP. P-gp inducers (eg, rifampin, St. John’s wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.

The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and multiple global markets. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and yellow fever. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding BioCryst’s plans and expectations for ORLADEYO. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; BioCryst’s ability to successfully implement its commercialization plans for, and to commercialize, ORLADEYO, which could take longer or be more expensive than planned; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; the results of our partnership with NewBridge may not meet our current expectations; the FDA, Saudi FDA, or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay, or withdraw market approval for products and product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s forward-looking statements.


Investor Contact:
John Bluth
+1 919 859 7910

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586

Primary Logo

Source: BioCryst Pharmaceuticals, Inc.

2022 GlobeNewswire, Inc., source Press Releases

09/15Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran..
09/14BioCryst Pharmaceuticals Names Chief Medical Officer
09/14Biocryst Pharmaceuticals Inc : Change in Directors or Principal Officers, Regulation FD Di..
09/14BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold..
09/14BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Ap..
09/06BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/31BioCryst to Present at Upcoming Investor Conferences
08/31BioCryst Pharmaceuticals Receives Orphan Drug Designation for Bone Disorder Treatment
08/31FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Tre..
08/31FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Tre..
More news
Analyst Recommendations on BIOCRYST PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 274 M - -
Net income 2022 -228 M - -
Net cash 2022 30,8 M - -
P/E ratio 2022 -10,3x
Yield 2022 -
Capitalization 2 380 M 2 380 M -
EV / Sales 2022 8,57x
EV / Sales 2023 6,55x
Nbr of Employees 358
Free-Float 99,0%
Duration : Period :
BioCryst Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCRYST PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 11
Last Close Price 12,80 $
Average target price 18,30 $
Spread / Average Target 43,0%
EPS Revisions
Managers and Directors
Jon P. Stonehouse Chief Executive Officer & Director
Michael L. Jones Executive Director-Finance
Anthony Doyle Chief Financial Officer
Robert Alexander Ingram Chairman
Helen M. Thackray Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-14.17%77 320
BIONTECH SE-47.68%32 778
WUXI APPTEC CO., LTD.-39.54%29 044